Immunocore (IMCR)
| Bid | 27.18 |
| Market Cap | 1.51B |
| Revenue (ttm) | 310.2M |
| Net Income (ttm) | -51.09M |
| EPS (ttm) | -1.02 |
| PE Ratio (ttm) | -29.56 |
| Forward PE | -21.6 |
| Analyst | Buy |
| Ask | 32 |
| Volume | 85,091 |
| Avg. Volume (20D) | 312,470 |
| Open | 30.01 |
| Previous Close | 30.10 |
| Day's Range | 29.67 - 30.59 |
| 52-Week Range | 23.15 - 62.74 |
| Beta | 0.76 |
About IMCR
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (N...
Analyst Forecast
According to 16 analyst ratings, the average rating for IMCR stock is "Buy." The 12-month stock price forecast is $66, which is an increase of 118.91% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago · seekingalpha.com
Immunocore: A Commercial Biotech Nearing Its Pivotal Break-Even PointImmunocore Holdings focuses on immunotherapy for oncology, with tebentafusp approved for metastatic uveal melanoma and brenetafusp in advanced trials. IMCR's strong balance sheet, with over $800 milli...
